RELIEF THERAPEUTICS N overview

GENEVA, SWITZERLAND / ACCESSWIRE / May 3, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, today announced the implementation timeline for the reverse split of its ordinary shares, which was approved by shareholders at the Extraordinary General...

Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares 03.05.2023 / 07:00 CET/CEST Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares GENEVA (May 3, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF , OTCQB: RLFTF , RLFTY ) (Relief Therapeutics), a biopharmaceutical company committed to delivering innovative treatment options with the potential for...

Acer reports OLPRUVA™ drug availability anticipated in mid-June 2023; Acer is engaged in discussions with payers representing a substantial majority of covered lives; 70 percent of metabolic treatment providers surveyed by Acer at SIMD Annual Meeting indicated an interest in treating at least one of their patients with OLPRUVA™ in 2023 GENEVA, SWITZERLAND / ACCESSWIRE / May 1, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics), a...

Relief Therapeutics Holding SA / Key word(s): Market Launch Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule 01-May-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule Acer reports OLPRUVA™ drug availability...

Shareholders approved all proposals by a large majority; Company to effectuate consolidation of ordinary shares in advance of planned Nasdaq Stock Market dual listing; ADR program will be terminated upon Nasdaq listing GENEVA, SWITZERLAND / ACCESSWIRE / April 28, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF, RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes...

Relief Therapeutics Holding SA / Key word(s): AGMEGM Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders 28.04.2023 / 19:00 CET/CEST Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders Shareholders approved all proposals by a large majority; Company to effectuate consolidation of ordinary shares in advance of planned Nasdaq Stock Market dual listing; ADR program will be terminated upon Nasdaq listing GENEVA (April 28, 2023)...

Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100 ® (Aviptadil Acetate) Relief to file a revised provisional patent application for RLF-100 ® based on the new stability results GENEVA, SWITZERLAND / ACCESSWIRE / April 17, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics, or Relief), a biopharmaceutical company committed to delivering innovative treatment options with the...

Relief Therapeutics Holding SA / Key word(s): Research Update Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100 17-Apr-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100 ® (Aviptadil Acetate) Relief to file a revised...